Mefenamic Acid

Kolkata: Prices of 42 medicines, including those used for day-to-day consumption, are likely to change following an order by the National Pharmaceutical Pricing Authority (NPPA). While some of the medicines will become cheaper, prices of others will increase. The 42 formulations under review include a number of anti-diabetes combination medicines like Sitagliptin, Dapagliflozin, Glimepiride, Metformin Hydrochloride, and Empagliflozin, among others. Prices of formulations like Telmisartan, Chlorthalidone (used to treat high blood pressure), and Clinidipine (used for treating hypertension) were also changed. Prices of medicines like Ezetimibe (used to treat high blood cholesterol), Atorvastatin (used to treat cardiovascular disease), Diclofenac Sodium (for treating inflammation/swelling), and Cefadroxil (broad-spectrum antibiotic) were also changed. A combination drug—Tranexamic Acid and Mefenamic Acid, often used in the treatment of heavy menstrual bleeding and pain, will become cheaper by Rs 18 per tablet. Another formulation, like Telmisartan Cilnidipine and Chlorthalidone tablets, will become cheaper by Rs 10 per tablet. The ceiling price of Amoxicillin 1g and Clavulanic Acid 200 mg injection has been revised from Rs 140.6 per vial to Rs 141.7 per vial. "The NPPA changed the pricing of some of the anti-cancer formulations a few days ago. This is the second change in prices of medicines this year," said Rajiv Singhal, General Secretary of the All India Organisation of Chemists and Druggists (AIOCD). The authority, in another notification, revised the ceiling prices of Azithromycin 250 mg tablets and a combination of Amoxicillin and Clavulanic Acid injection. "Prices of some medicines have dropped. For some other medicines, we are expecting a rise in prices by at least 10%. Since these are used on a regular basis by many patients, their medicine bills will change now," said Prithwi Bose, general secretary of the Bengal Chemists and Druggists Association (BCDA). According to Somnath Ghosh of Metro Pharma, the new batch of medicines with the changed MRP will take at least 90 days to arrive. "We are expecting the new batches to arrive by the end of March. However, the companies tend to dry out the old stock before sending the new batch. That might cause some trouble for the patients," Ghosh said. By

MONDAY, Jan. 6, 2025 -- Gestational exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk for childhood chronic kidney disease (CHD), although the association is not seen in sibling comparisons, according to a study published online Dec. 23 in JAMA Pediatrics . You-Lin Tain, M.D., Ph.D., from Kaohsiung Chang Gung Memorial Hospital and the Chang Gung University College of Medicine in Taiwan, and colleagues examined the association between gestational exposure to NSAIDs and the risk for CKD in childhood in a cohort study involving 1,025,255 children born alive in Taiwan from Jan. 1, 2007, to Dec. 31, 2017, with follow-up until Dec. 31, 2021. The study included 163,516 singleton-born children whose mothers used at least one dispensing of an NSAID during pregnancy. The researchers observed a significant association between gestational NSAID exposure and a higher risk for childhood CKD (weighted hazard ratio [wHR], 1.10). In sibling comparisons, there was no association seen between NSAID use and fetal nephrotoxicity. In singleton-born children, increased risks were seen for exposure during the second and third trimesters (wHRs, 1.19 and 1.12, respectively). Specific NSAID exposures associated with elevated CKD risk included indomethacin and ketorolac in the first trimester (wHRs, 1.69 and 1.28, respectively); diclofenac and mefenamic acid in the second trimester (wHRs, 1.27 and 1.29, respectively); and ibuprofen in the third trimester (wHR, 1.34). "Future research should investigate the specific roles of genetic and environmental factors in kidney development across different stages of pregnancy," the authors write. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.